Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AZD1656 Clear all
Completed Phase 1 Interventional

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

NCT00995787
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

NCT01096940
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

To Evaluate the Response to Glucagon During Hypoglycemia

NCT00817271
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Glucagon
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 6, 2009 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

NCT00747175
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

NCT01103622
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Digoxin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2011 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

To Evaluate the Bioavailability of a Tablet of AZD1656

NCT00817505
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

To Evaluate 24-hr Glucose After OD vs BD AZD1656

NCT00819884
View directory record Official record
Conditions
Type II Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2009 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00817778
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

NCT01069926
View directory record Official record
Conditions
Glucose Lowering
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Orlando, Florida • Overland Park, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

NCT00960791
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, High Blood Sugar
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

NCT00774553
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

NCT00741689
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

NCT00768105
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

NCT01221545
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

NCT00790153
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin, AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2009 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

NCT00726427
View directory record Official record
Conditions
Healthy
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

NCT00856908
View directory record Official record
Conditions
Type II Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 3, 2026, 12:47 AM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2010 · Synced Sep 3, 2026, 12:47 AM EDT